AC

Aquilo Capital Management, LLC

Momentum followerHigh-turnover traderConcentrated strategy

Total reported value

$238.9M

Reporting period: 2018-09-30 · Number of holdings: 13

Aquilo Capital Management, LLC disclosed 13 holdings in its latest 13F filing for the period ending 2018-09-30, with total reported value of $238.9M and a quarterly turnover rate of 87.1%.

Personality snowflake

Concentration
92.79
Portfolio Stability
87.14
Momentum/Contrarian
100
Sector conviction
0
Diversification
24
Sizing Uniformity
86.05

Recent moves

  • Add XBI

    +83.3%　$104.1M

  • Trim N5749R100

    +3.6%　-$2.9M

  • Trim 548862101

    -13.8%　-$3.3M

  • Trim CTMX

    +3.8%　-$2.4M

  • Trim ADROEUR

    +4.8%　$1.4M

  • Trim PIRSEUR

    0.0%　$1.0M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

Showing top 12 holdings (of 13 total)

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1XBISs Spdr S&p Biotech ETFETF-Tech44.14%+43.02%+83.33%
2✓ Merus N VStock-Other10.70%-12.78%+3.58%
3✓ Loxo Oncology INCStock-Other7.82%-10.32%-13.80%
4FATEFate Therapeutics INCStock-Other6.71%+1.28%+69.69%
5ADROEURChinook Therapeutics INCStock-Other6.48%-5.11%+4.85%
6✓ Synlogic INCStock-Other5.94%+3.45%+225.31%
7CTMXCytomx Therapeutics INCStock-Other5.22%-7.03%+3.85%
8PIRSEURPieris Pharmaceuticals INCStock-Other4.63%-3.63%—
9SPROSpero Therapeutics INCStock-Other3.52%-1.52%+91.91%
10XENEXenon Pharmaceuticals INCStock-Other3.27%+3.27%NEW
11LKFTLakefront Biotherapeutic-adrStock-Other1.47%-3.55%-52.58%
12MOR2Morphosys AG AdrStock-Other0.10%-0.15%-9.13%

Holding changes this quarter

Aquilo Capital Management, LLC's most significant position changes for 2018-09-30: New buy: Xenon Pharmaceuticals INC (XENE); Sold out: Autolus Therapeutics PLC (AUTL); Sold out: Cellectis - Adr (CLLS); Sold out: Five Prime Therapeutics INC (FPRX); Add: Ss Spdr S&p Biotech ETF (XBI) — shares +83.33%.

Position changes disclosed by Aquilo Capital Management, LLC for the quarter ending 2018-09-30, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1XBISs Spdr S&p Biotech ETF+43%+83.33%Add
2✓ Synlogic INC+3.5%+225.31%Add
3FATEFate Therapeutics INC+1.3%+69.69%Add
4MOR2Morphosys AG Adr-0.2%-9.13%Trim
5SPROSpero Therapeutics INC-1.5%+91.91%Add
6LKFTLakefront Biotherapeutic-adr-3.6%-52.58%Trim
7PIRSEURPieris Pharmaceuticals INC-3.6%—Unchanged
8ADROEURChinook Therapeutics INC-5.1%+4.85%Add
9CTMXCytomx Therapeutics INC-7%+3.85%Add
10✓ Loxo Oncology INC-10.3%-13.80%Trim
11✓ Merus N V-12.8%+3.58%Add
12XENEXenon Pharmaceuticals INC—NEWNew buy
13AUTLAutolus Therapeutics PLC—EXITSold out
14CLLSCellectis - Adr—EXITSold out
15FPRXFive Prime Therapeutics INC—EXITSold out

FAQ

What is Aquilo Capital Management, LLC and what type of investor is it?
Aquilo Capital Management, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2018-09-30), the firm manages a tracked equity portfolio valued at approximately $238.9M, spread across 13 disclosed positions.
What are Aquilo Capital Management, LLC's largest equity positions?
Based on the latest 13F filing, Aquilo Capital Management, LLC's top holdings by market value are: 1. Ss Spdr S&p Biotech ETF (XBI) — $105.5M (44.1%) 2. Merus N V — $25.6M (10.7%) 3. Loxo Oncology INC — $18.7M (7.8%) 4. Fate Therapeutics INC (FATE) — $16.0M (6.7%) 5. Chinook Therapeutics INC (ADROEUR) — $15.5M (6.5%)
What changes did Aquilo Capital Management, LLC make in its most recent portfolio filing?
In the latest reported quarter, Aquilo Capital Management, LLC made 14 notable position adjustments: 1 new positions were initiated, 7 existing holdings were added to, 3 positions were partially reduced, and 3 were completely exited. The largest of these moves: New buy: Xenon Pharmaceuticals INC (XENE); Sold out: Autolus Therapeutics PLC (AUTL); Sold out: Cellectis - Adr (CLLS); Sold out: Five Prime Therapeutics INC (FPRX); Add: Ss Spdr S&p Biotech ETF (XBI) — shares +83.33%
What sectors does Aquilo Capital Management, LLC focus on?
Sector breakdown data is not yet available for Aquilo Capital Management, LLC. Check back after the next 13F processing cycle.